Cardiac sympathetic dysfunction in left ventricular hypertrophy caused by arterial hypertension and degenerative

Riccardo Liga1, Alessia Gimelli2, Marco De Carlo3

  • 1Cardiac, Thoracic and Vascular Department, University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy. riccardo.liga@gmail.com.

Insights

Cardiac sympathetic innervation is impaired in patients with left ventricular hypertrophy (LVH), with or without aortic stenosis (AS). The transcatheter aortic valve implantation (TAVI) procedure did not significantly impact cardiac sympathetic function.

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Cardiovascular Imaging

Background:

  • Hypertension and aortic stenosis (AS) can lead to left ventricular hypertrophy (LVH).
  • Cardiac sympathetic dysfunction is implicated in cardiovascular disease progression.
  • Assessing cardiac sympathetic innervation is crucial in patients with LVH and AS.

Purpose of the Study:

  • To evaluate cardiac sympathetic innervation in patients with LVH and AS undergoing transcatheter aortic valve implantation (TAVI).
  • To compare sympathetic innervation in patients with LVH and AS, essential hypertension (HT), and controls.
  • To assess the impact of TAVI on cardiac sympathetic innervation.

Main Methods:

  • Utilized 123I-metaiodobenzylguanidine (MIBG) and 99mTc-tetrofosmin SPECT imaging.
  • Assessed sympathetic innervation and left ventricular (LV) perfusion.
  • Calculated innervation/perfusion mismatch score as an indicator of cardiac sympathetic dysfunction.

Main Results:

  • Patients with AS and LVH, and those with essential HT and LVH, showed higher innervation/perfusion mismatch scores than controls.
  • Significant LVH was identified as the primary predictor of impaired LV sympathetic innervation.
  • No significant changes in LV sympathetic innervation were observed 6 months post-TAVI, despite a marginal reduction in LV mass.

Conclusions:

  • Cardiac sympathetic innervation is demonstrably impaired in patients with LVH, irrespective of AS.
  • The TAVI procedure does not significantly alter cardiac sympathetic innervation in this patient cohort.
  • LVH is a key factor influencing cardiac sympathetic dysfunction.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
568
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
2.1K
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
269
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
252
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
239
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
307